Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nautilus Biotechnolgy ( (NAUT) ) has shared an update.
On January 27 and 28, 2025, Vijay Pande and Michael Altman informed Nautilus Biotechnology that they will not stand for re-election to the board of directors at the 2025 annual meeting. Their decision is not due to any disagreements with the company’s operations, policies, or practices, indicating stability and alignment in the company’s strategic direction.
More about Nautilus Biotechnolgy
Nautilus Biotechnology operates within the biotechnology industry, focusing on developing innovative technologies for protein analysis and identification.
YTD Price Performance: 4.73%
Average Trading Volume: 146,417
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $222.2M
See more insights into NAUT stock on TipRanks’ Stock Analysis page.